Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 2

4-aminopyridine for Skin Wound Healing

John Elfar · NCT06333171

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–70 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 2
Target enrollment
150
US sites recruiting
1
Study start
September 2025
Record last updated
September 3, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults.

The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing.

The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.

Being studied: 4-Aminopyridine; Placebo

Conditions: Wounds; Wound of Skin; Wound Heal; Wounds and Injuries

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.
  • Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.
  • Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).
  • Adults subject aged 18-70
  • Ability to give written informed consent.
  • Capable of safely coming in for follow up visits on all scheduled appointments.

Exclusion Criteria

  • History of multiple sclerosis, stroke or any other diagnosed neurological disorder
  • History of hypersensitivity to AMPYRA® or 4-aminopyridine
  • Current use of aminopyridine medications, including other compounded 4-AP
  • Suspected renal impairment based on the Choyke questionnaire.
  • History of difficult compliance with timely follow up
  • Patients outside the age range
  • Unable to provide informed consent.
  • Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).
  • Patients with a concomitant traumatic brain injury.
  • Patients unable to communicate.
  • Patients unwilling to complete the study requirements.
  • Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.
  • Pregnancy, breastfeeding or incarcerated individuals.
  • Non-English speaking
  • Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds

Recruiting US locations

  • University of Arizona

    Tucson, AZ 85724

    Site contact: Andrea Horne · 520-626-6456 · ahh@arizona.edu

Study contacts (from the official record)

  • Andrea Horne · 520-626-6456 · ahh@arizona.edu
All healthy volunteers studies in Arizona →
4-aminopyridine for Skin Wound Healing (NCT06333171) | Bored Studies